Posted: November 12, 2019
Application Deadline: Open Until Filled
The position is available in Cancer Biology at the Lerner Research Institute at the Cleveland Clinic. We are seeking a highly motivated and independent scientist to study mechanisms of resistance to targeted therapy in lung cancer. We have shown that resistant mutations are acquired through cytosine deaminase (1). We are utilizing different in vitro and in vivo approaches to:
1) Determine whether the same mechanism is responsible for new resistant mutations to inhibitors of various pathways.
2) Determine whether a specific subpopulation has the ability to induce this mechanism of resistance.
3) Assess the role of cytosine deaminase in other resistant mechanisms.
4) Developing new pharmacologic therapies to prevent/delay resistance.
Candidates should have a recent PhD or MD and experience in molecular and cell biology, biochemistry and related disciplines. Excellent verbal and communication skills are required. The Cleveland Clinic Lerner Research Institute provides an excellent interactive environment with access to state-of-the-art equipment and facilities. Interested applicants please submit a CV and contact information for 3 references to Khaled Hassan, MD.MS. via email email@example.com.
1) The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. Cancer Res. 2018 Dec 15;78(24):6728-6735.
Cleveland Clinic is pleased to be an equal employment/affirmative action employer: Women/Minorities/Veterans/Individuals with Disabilities. Smoke/drug free environment.